The New England journal of medicine 2015-02-19
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Abstract
Background
In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the median being reached. We report final prespecified overall survival results with a median follow-up of 50 months.
Methods
We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination. The secondary end points of overall survival, investigator-assessed progression-free survival, independently assessed duration of response, and safety are reported. Sensitivity analyses were adjusted for patients who crossed over from placebo to pertuzumab after the interim analysis.
Results
The median overall survival was 56.5 months (95% confidence interval [CI], 49.3 to not reached) in the group receiving the pertuzumab combination, as compared with 40.8 months (95% CI, 35.8 to 48.3) in the group receiving the placebo combination (hazard ratio favoring the pertuzumab group, 0.68; 95% CI, 0.56 to 0.84; P<0.001), a difference of 15.7 months. This analysis was not adjusted for crossover to the pertuzumab group and is therefore conservative. Results of sensitivity analyses after adjustment for crossover were consistent. Median progression-free survival as assessed by investigators improved by 6.3 months in the pertuzumab group (hazard ratio, 0.68; 95% CI, 0.58 to 0.80). Pertuzumab extended the median duration of response by 7.7 months, as independently assessed. Most adverse events occurred during the administration of docetaxel in the two groups, with long-term cardiac safety maintained.
Conclusions
In patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared with the addition of placebo, significantly improved the median overall survival to 56.5 months and extended the results of previous analyses showing the efficacy of this drug combination. (Funded by F. Hoffmann-La Roche and Genentech; CLEOPATRA ClinicalTrials.gov number, NCT00567190.).
Related Questions
How would you manage an elderly patient with a history of stage I CLL and newly diagnosed metastatic ER+/HER2+ breast cancer?
The focus would be on the diagnosis which seems most likely to be life-limiting and/or a source of morbidity. Although there aren't many details here regarding the metastatic ER+ HER2+ breast cancer (e.g. where are the mets? Bone? Liver? Are there symptoms?) one presumes that this is more life-limit...
What is the best second line treatment for a HER2+ metastatic breast cancer treated with frontline paclitaxel and anti-HER2 therapy?
I would use T-DM1 (ado trastuzumab emtansine) in this situation as a second line therapy. T-DM1 has a very favorable side effect profile. Pertuzumab added a survival benefit when combined docetaxel and trastuzumab (median of 15.7 months) though this was a first-line treatment (Swain et al. NEJM 2015...
What is your preferred regimen for triple positive breast cancer with visceral metastasis while on adjuvant AI?
My preferred regimen in this clinical situation would be to start with a taxane-based regimen plus trastuzumab and pertuzumab, per the CLEOPATRA trial. In this study, there is a highly significant and clinically meaningful overall survival advantage to adding pertuzumab in patients with newly metast...
What is your preferred regimen for triple positive breast cancer with bone only recurrence?
The primary options for triple positive MBC is whether to use antiestrogen approaches alone or with antiHER2 therapy, versus chemotherapy + HP. Indolent disease with bone-only involvement is the group for which antiestrogen-based approaches alone could be considered, although two randomized studies ...
Is it safe to offer breast/chest wall radiotherapy while a patient is receiving Perjeta?
The question of concurrent pertuzumab and radiation in the palliative setting will likely come up more often now with the recent striking improvement in overall survival of 15.7 months in stage IV HER2+ patients treated with docetaxel pertuzumab and trastuzumab as compared with docetaxel and hercept...